Hong Li

Dr. Hong Li

Associate

Details

About

Dr Li is the Associate of School of Science. His research focuses on the clinical effects and mechanisms of natural products for cancers, infectious diseases and metabolic diseases through the network-based investigation which links to drug discovery.

Dr Li utilises supercomputers to perform computational modelling and screening to seek the synergistic effects of compounds in natural products. He also investigates the mechanisms of action of Chinese herbal formulae for cancers, infectious diseases and metabolic diseases via network pharmacological analysis.

Awards:
Deputy Vice-Chancellor’s Higher Degree by Research Prize, RMIT University, 2021

Research funding:
- Supercomputer and structure-based multi-ligand molecular modeling for the synergistic effects of Danggui Beimu Kushen Wan and abiraterone in the treatment of castrate-resistant prostate cancer, funded by National Natural Science Foundation of China, from 2023 to 2025, Grant No. 8220140209, CNY 300,000, Principal Investigator;

- Supercomputing structure-based multi-ligands molecular modeling to investigate the cooperativity of Danggui Beimu Kushen Wan and abiraterone for castrate-resistant prostate cancer, funded by China Postdoctoral Science Foundation, from 2022 to 2023, Grant No.: 2022M711534, CNY 80,000, Principal Investigator;

- Supercomputing SMMM technology to explore the synergistic mechanism of Danggui Beimu Kushen Wan with abiraterone in the treatment of CRPC, funded by Guangdong Basic and Applied Basic Research Foundation, China, from 2021 to 2024, Grant No.: 2021A1515110082, CNY 100,000, Principal Investigator; 

- Supercomputer virtual screening and network pharmacology of Danggui Beimu Kushen Wan on Cytochrome P450 family for prostate cancer, funded by Human Resources and Social Security Department of Guangdong Province, China, from 2021 to 2022, no grant number, CNY 100,000, Principal Investigator.


Professional interests:
Young Editorial Board Member
- Traditional Medicine Research
- Medical Data Mining

Reviewer for peer-reviewed journals
- Frontiers in Pharmacology (SCI, IF: 5.988)
- Frontiers in Nutrition (SCI, IF: 6.59)
- Frontiers in Cell and Developmental Biology (SCI, IF: 6.018)
- Frontiers in Oncology (SCI, IF: 5.738)
- Evidence-based Complementary and Alternative Medicine (SCI, IF: 2.65)
- Journal of Pharmacy and Pharmacology (SCI, IF: 4.81)
- Alternative Therapies in Health and Medicine (SCI, IF: 1.804)
- Traditional Medicine Research (ESCI)
- Cancer Advances
- Precision Medicine Research
- Medical Data Mining

Research fields

  • 3404 Medicinal and biomolecular chemistry
  • 3406 Physical chemistry
  • 4004 Chemical engineering
  • 4208 Traditional, complementary and integrative medicine
  • 4203 Health services and systems
  • 4205 Nursing
  • 3202 Clinical sciences
  • 3204 Immunology
  • 3205 Medical biochemistry and metabolomics
  • 3211 Oncology and carcinogenesis

Research interests

- Computational modelling and simulations of biomolecular systems
- Synergistic effects of compounds in natural products
- Computer-aided novel combination drug discovery
- Systematic reviews and meta-analysis on effects and safety of Chinese herbal medicine for chronic diseases
- Randomised controlled clinical trials of Chinese herbal medicine for chronic diseases
aboriginal flag
torres strait flag

Acknowledgement of Country

RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business - Artwork 'Sentient' by Hollie Johnson, Gunaikurnai and Monero Ngarigo.